Skip to content
value.today

Glycoregimmune, Inc.

Total raised
$10 M
2 rounds on record
Latest round
$6 M
Nov 2018
First round on record
Apr 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Glycoregimmune, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2023$16 MIssued in a merger or acquisition$10 to $50 million

Glycoregimmune, Inc.: Private sale, Apr 2023

Investors in this round

1 investor had bought by the notice of Apr 28, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$245,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Walter Marc Hertz · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ecoban Securities Corporation (CRD 29112) · New York, New YorkSold in NY

Signed by W. Marc Hertz, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 28, 2023. Read the notice at the SEC.

equity, optionsSEC
Nov 2018$6 MNo. 2$2 to $10 million

Glycoregimmune, Inc.: Raise no. 2, Nov 2018

Investors in this round

4 investors had bought by the notice of Nov 8, 2018: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sean G Edwards · Executive Officer
  • W Marc Hertz · Executive Officer, Director
  • Abraham Marc Van Wyck · Director
  • Albert Marc Agro · Director
  • Gerald Marc Yakatan · Director
  • Vipin Marc Kumar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by /S/ W. Marc Hertz, Chief executive officer. Source: SEC Form D, newest notice filed Nov 8, 2018. Read the notice at the SEC.

equity, debt, optionsSEC
Apr 2015$4 MNo. 1$2 to $10 million

Glycoregimmune, Inc.: Raise no. 1, Apr 2015

Investors in this round

2 investors had bought by the notice of Apr 17, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Oppel Kumar Greef · Executive Officer
  • Vipin Kumar Chaturvedi · Executive Officer, Director
  • Walter Marc Hertz · Executive Officer, Director
  • Abraham Kumar Van Wyk · Director
  • Albert Marc Agro · Director
  • Raymond Kumar Watt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Walter Marc Hertz, President and CEO. Source: SEC Form D, newest notice filed Apr 17, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Glycoregimmune, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2023).

    SEC Form D · Apr 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Apr 2023

That is all the official record says: Glycoregimmune, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Glycoregimmune, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 4 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Glycoregimmune, Inc.
NameRoleNamed in
Walter Marc HertzExecutive officerApr 2023
Sean G EdwardsExecutive officerNov 2018
W Marc HertzExecutive officerNov 2018
Oppel Kumar GreefExecutive officerApr 2015
Vipin Kumar ChaturvediExecutive officerApr 2015
Walter Marc HertzDirectorApr 2023
Abraham Marc Van WyckDirectorNov 2018
Albert Marc AgroDirectorNov 2018
Gerald Marc YakatanDirectorNov 2018
Vipin Marc KumarDirectorNov 2018
W Marc HertzDirectorNov 2018
Abraham Kumar Van WykDirectorApr 2015
Raymond Kumar WattDirectorApr 2015
Vipin Kumar ChaturvediDirectorApr 2015